<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-5193-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NATRIXAM 1.5 MG/5 MG MR TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMLODIPINE BESILATE, INDAPAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1.5 , 5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        modified-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        38
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LES LABORATOIRES SERVIER INDUSTRIE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LES LABORATOIRES SERVIER INDUSTRIE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LES LABORATOIRES SERVIER 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C08GA02 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group: calcic inhibitors and diuretics - ATC code: C08GA02</p><p>Natrixam is prescribed as substitution treatment for high blood pressure (hypertension) in patients already taking indapamide and amlodipine from separate tablets in the same strength.</p><p>Natrixam is a combination of two active ingredients, indapamide and amlodipine.</p><p>Indapamide is a diuretic. Diuretics increase the amount of urine produced by the kidneys. However, indapamide is different from other diuretics, as it only causes a slight increase in the amount of urine produced. Amlodipine is a calcium antagonist (which belongs to a class of medicines called dihydropyridines) and it works by relaxing blood vessels, so that blood passes through them more easily.</p><p>Each of the active ingredients reduces blood pressure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Natrixam:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to indapamide or any other sulfonamide (group of medicinal product for the treatment of hypertension), or to amlodipine or any other calcium antagonist (group of medicinal product for the treatment of hypertension) or to any of the other ingredients of this medicine (listed in section 6). This may be itching, reddening of the skin or difficulty in breathing,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe low blood pressure (hypotension),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have narrowing of the aortic heart valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from heart failure after a heart attack,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe kidney disease,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver disease or suffer from a condition called hepatic encephalopathy (disease of the brain caused by liver illness),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have low potassium levels in your blood,</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking Natrixam if you have or have had any of the following conditions:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; recent heart attack,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart failure, any heart rhythm problems, if you have coronary artery disease (heart disease caused by poor blood flow in the blood vessels of the heart),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have problems with your kidneys,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience a decrease in vision or eye pain. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase of pressure in your eye and can happen within hours to weeks of taking Natrixam. This can lead to permanent vision loss, if not treated. If you earlier have had a penicillin or sulfonamide allergy, you can be at higher risk of developing this,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have muscle disorders including muscle pain, tenderness, weakness or cramps,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe increase in blood pressure (hypertensive crisis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are elderly and your dose needs to be increased,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you take other medicines,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are malnourished,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from gout,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you need to have a test to check how well your parathyroid gland is working,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had photosensitivity reactions.</p><p>&nbsp;</p><p>Your doctor may prescribe you blood tests to check for low sodium or potassium levels or high calcium levels.</p><p>If you think any of these situations may apply to you or you have any questions or doubts about taking your medicine, you should consult your doctor or pharmacist.</p><p>Athletes should be aware that Natrixam contains an active ingredient which may give a positive reaction in drug tests.</p><p><strong>Children and adolescents</strong></p><p>Natrixam should not be given to children and adolescents.</p><p><strong>Other medicines </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p><strong>You should not take Natrixam:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with lithium (used to treat mental disorders such as mania, manic depressive illness and recurrent depression) due to the risk of increased levels of lithium in the blood,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with dantrolene (infusion for severe body temperature).</p><p>&nbsp;</p><p>Make sure to tell your doctor if you are taking any of the following medicines, as special care may be required:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines for treating high blood pressure,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used for heart rhythm problems (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, bretylium),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat mental disorders such as depression, anxiety, schizophrenia&hellip; (e.g.&nbsp;tricyclic antidepressants, antipsychotic drugs, neuroleptics) (such as amisulpride, sulpiride, sultopride, tiapride, haloperidol, droperidol)),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bepridil (used to treat angina pectoris, a condition causing chest pain),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cisapride, diphemanil (used to treat gastro-intestinal problems),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vincamine IV (used to treat symptomatic cognitive disorders in elderly including memory loss),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; halofantrine (antiparasitic drug used to treat certain types of malaria),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pentamidine (used to treat certain types of pneumonia),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antihistamines used to treat allergic reactions, such as hay fever (e.g mizolastine, astemizole, terfenadine),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-steroidal anti-inflammatory drugs for pain relief (e.g. ibuprofen) or high doses of acetylsalicylic acid,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angiotensin converting enzyme (ACE) inhibitors (used to treat high blood pressure and heart failure),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral corticosteroids used to treat various conditions including severe asthma and rheumatoid arthritis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digitalis preparations (for the treatment of heart problems),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stimulant laxatives,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; baclofen (to treat muscle stiffness occurring in diseases such as multiple sclerosis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; potassium-sparing diuretics (amiloride, spironolactone, triamterene),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metformin (to treat diabetes),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; iodinated contrast media (used for tests involving X-rays),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; calcium tablets or other calcium supplements,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immunosuppressants (medicines used to control your body&rsquo;s immune response) for the treatment of auto-immune disorders or following transplant surgery (e.g. ciclosporine, tacrolimus),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sirolimus, temsirolimus, everolimus and other drugs belonging to the class of so-called mTOR inhibitors (medicines used to alter the way your immune system works),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tetracosactide (to treat Crohn&rsquo;s disease),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antifungal medicines (e.g ketoconazole, itraconazole, amphotericin B by injection),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir, indinavir, nelfinavir (so called protease inhibitors used to treat HIV),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics used to treat bacterial infections (e.g rifampicin, erythromycin by injection, clarithromycin, sparfloxacin, moxifloxacin),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>hypericum perforatum</em> (St. John&rsquo;s Wort),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; verapamil, diltiazem (heart medicines),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; simvastatin (cholesterol lowering medicine),&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allopurinol (to treat gout).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methadone (used to treat addiction).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Natrixam with food and drink </strong></p><p>Grapefruit juice and grapefruit should not be consumed by people who are taking Natrixam. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active ingredient amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Natrixam.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>This medicine is not recommended during pregnancy. When a pregnancy is planned or confirmed, the switch to an alternative treatment should be initiated as soon as possible.</p><p>Natrixam is not recommended if you are breast-feeding. Tell your doctor immediately if you are breast‑feeding or about to start breast-feeding.</p><p><strong>Driving and using machines</strong></p><p>Natrixam may affect your ability to drive or use machines. If the tablets make you feel sick, dizzy or tired, or give you a headache, do not drive or use machines and contact your doctor immediately. If this occurs, you should refrain from driving and other activities requiring alertness.</p><p><strong>Natrixam contains lactose monohydrate. </strong></p><p>The use of this medicine is not recommended in patients with rare hereditary problems of galactose intolerance, a total lactase deficiency or glucose-galactose malabsorption. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p><strong>Natrixam contains sodium.</strong></p><p>Natrixam contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is one tablet once a day, preferably in the morning.</p><p>The tablet should be swallowed whole with water and should not be chewed.</p><p><strong>If you take more Natrixam 1.5 mg/5 mg modified-release tablets than you should</strong></p><p><strong>&nbsp;</strong></p><p>Contact your doctor or pharmacist immediately.</p><p>Taking too many tablets may cause your blood pressure to become low or even dangerously low. You may feel dizzy, drowsy, weak or you may faint. You may experience nausea, vomiting, cramps, confusion and changes in the amount of urine produced by the kidneys. If a blood pressure drop is severe enough shock can occur. Your skin could feel cool and clammy and you could lose consciousness.</p><p><strong>If you forget to take Natrixam 1.5 mg/5 mg modified-release </strong></p><p>Do not worry. If you forget to take a tablet, take your next dose at the right time.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Natrixam 1.5 mg/5 mg modified-release tablets </strong></p><p>As the treatment for high blood pressure is usually life-long, you should discuss with your doctor before stopping this medicinal product.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Stop taking Natrixam and visit your doctor immediately if you experience any of the following side effects that can be serious:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of eyelids, face or lips (very rare, may affect up to 1 in 10,000 people),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the tongue and throat which causes great difficulty breathing (very rare, may affect up to 1 in 10,000 people),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens Johnson syndrome, toxic epidermal necrolysis) or other allergic reactions (very rare, may affect up to 1&nbsp;in 10,000 people),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack (very rare, may affect up to 1 in 10,000 people); life-threatening irregular beat (torsade de pointes) (frequency not known),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart beat (uncommon, may affect up to 1 in 100 people),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed pancreas which may cause severe abdominal and back pain accompanied with feeling very unwell (very rare, may affect up to 1 in 10,000 people).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness, cramps, tenderness or pain and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown (Not known).</p><p>&nbsp;</p><p>&nbsp;</p><p>In decreasing order of frequency, other side effects can include:</p><p><strong>Very common: may affect </strong><strong>more than 1 in 10 people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oedema (fluid retention).</p><p>&nbsp;</p><p><strong>Common: may affect up to 1 in 10 people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, dizziness, sleepiness (especially at the beginning of treatment),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual impairment, double vision,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations (awareness of your heart beat), flushing (feeling of warmth on the face),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain, feeling sick (nausea), change of bowel habit, diarrhoea, constipation, indigestion,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ankle swelling, tiredness, weakness, muscle spasms,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low potassium in the blood, which may cause muscle weakness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rashes.</p><p>&nbsp;</p><p><strong>Uncommon: may affect up to 1 in 100 people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mood altered, anxiety, depression, sleeplessness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trembling,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; taste abnormalities,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness or tingling sensation in your limbs; loss of pain sensation,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sneezing/running nose caused by inflammation of the lining of the nose (rhinitis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough, dry mouth, vomiting (nausea),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss, increased sweating, itchy skin, red patches on skin, skin discolouration, hives,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorder in passing urine, increased need to urinate at night, increased number of times of passing urine,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to obtain an erection; discomfort or enlargement of the breasts in men,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, feeling unwell,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint or muscle pain, back pain,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight increased or decreased.</p><p>&nbsp;</p><p><strong>Rare: may affect up to 1 in 1,000 people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusional state,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of dizziness.</p><p>&nbsp;</p><p><strong>Very rare: may affect up to 1 in 10,000 people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in blood cells, such as thrombocytopenia (decrease in the number of platelets which causes easy bruising and nasal bleeding), leucopenia (decrease of white blood cells which may cause unexplained fever, soreness of the throat or other flu-like symptoms &ndash; if this occurs, contact your doctor) and anaemia (decrease in red blood cells),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excess sugar in blood (hyperglycaemia),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of calcium in blood,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a disorder of the nerves which can cause weakness, tingling or numbness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the gums,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal bloating (gastritis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatic function abnormal, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), liver enzyme increase which may have an effect on some medical tests ; in cases of liver failure, there is a possibility of getting hepatic encephalopathy (disease in the brain caused by liver illness),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney disease,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased muscle tension,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of blood vessels, often with skin rash,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensitivity to light.</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes may occur in your laboratory parameters and your doctor may need to give you blood tests to check your condition. The following changes in laboratory parameters may occur:</p><p>o&nbsp;&nbsp; low sodium in the blood that may lead to dehydration and low blood pressure,</p><p>o&nbsp;&nbsp; increase in uric acid, a substance which may cause or worsen gout (painful joint(s) especially in the feet),</p><p>o&nbsp;&nbsp; increase in blood glucose levels in diabetic patients,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal ECG tracing,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; short sightedness (myopia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vision blurred.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in vision or pain in your eyes due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trembling, rigid posture, mask-like face, slow movements and a shuffling, unbalanced walk.&nbsp;</p><p>If you suffer from systemic lupus erythematosus (a type of collagen disease), this might get worse.</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet. You can also report side effects directly via the national reporting system:</p><p>By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>Store below 30 &deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are indapamide and amlodipine.</p><p>Indapamide.................................................................. 1.5 mg</p><p>Amlodipine..................................................................... 5 mg</p><p>Equivalent to amlodipine besilate............................... 6.935 mg</p><p>For one tablet</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&nbsp;</p><p><u>Core:</u> lactose monohydrate, hypromellose (E464), magnesium stearate (E572), povidone (E1201), silica colloidal anhydrous, calcium hydrogen phosphate dehydrate, cellulose microcrystalline (E460), croscarmellose sodium (E468), pregelatinized maize starch.</p><p><u>Film-coating:</u> glycerol (E422), hypromellose (E464), macrogol 6000, magnesium stearate (E572), titanium dioxide (E171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Natrixam tablets are white, round, film-coated, modified-release tablets of 9 mm diameter engraved with  on one face.
The tablets are available in blisters of 15, 30, 60, 90 tablets and tablet containers of 100 and 500 tablets. 
Not all pack sizes may be marketed.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder :<br />Les Laboratoires Servier<br />50, rue Carnot<br />92284 Suresnes cedex - France</p><p>Manufacturer:<br />Les Laboratoires Servier Industrie<br />905 route de Saran<br />45520 Gidy - France</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.</p><p><strong>&nbsp;&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:704px"><tbody><tr><td style="vertical-align:top"><p><strong>Saudi Arabia </strong></p><p>Servier Saudi Arabia Scientific Office</p><p>3533 As Sulaimaniyah - Hitteen Dist.</p><p>1st floor - Office #101</p><p>Kingdom of Saudi Arabia</p><p>Tel.: +966 011 252 2330</p><p>E-mail: regulatory.sa1@servier.com</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Gulf Countries </strong></p><p>Les Laboratoires Servier Scientific Office</p><p>P.O. Box 1586, Level 15, Arenco Tower, Dubai Media city, Sheikh Zayed Road,</p><p>Dubai, UAE</p><p>Tel: +971 4 3329903</p><p>E-mail: magdy.abdou@servier.com</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The date of preparation of the package for KSA 04.2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">الفئة العلاجية الصيدلانية: حاصرات للكلسيوم ومدرّات - &nbsp;الرقم الرمزي ATC: C08GA02</p><p dir="RTL">يوصف ناتريكسام لعلاج ارتفاع الضغط الشرياني لدى المرضى بدلا من استعمال أقراص إنداباميد وأملوديبين كل على حدة بنفس المقدار.</p><p dir="RTL">ناتريكسام عبارة عن مزيج من مادتين فعّالتين: إنداباميد و أملوديبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إنداباميد هو مدر للبول. ومعظم مدرات البول ترفع كمية البول التي تنتجها الكلي. إلا أن إنداباميد يختلف عن مدرات البول الأخرى لأنه لا ينتج إلا ارتفاعا طفيفا في كمية البول المنتجة. الأملوديبين حاصر للكلسيوم (تابع لصنف الأدوية المسمّاة ديهيدروبيريدين dihydropyridines). ويعمل على إرخاء الأوعية الدموية، بشكل يجعل الدم يمر عبرها بسهولة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تقوم هاتان المادتان الفعّالتان بتخفيض الضغط الشرياني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا يجوز على الإطلاق تناول ناتريكسام:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية من مادة الإنداباميد أو من أي سلفاميد آخر (الفئة الاستشفائية المستعملة في علاج ارتفاع الضغط الشرياني)، أو من الأملوديبين أو من أي حاصر آخر للكلسيوم (الفئة الاستشفائية المستعملة في علاج ارتفاع الضغط الشرياني) أو من أحد المكونات الأخرى التي يحتوي عليها هذا الدواء والمذكورة في القسم 6. ويمكن أن يظهر ذلك على شكل حكة أو احمرار الجلد أو صعوبة في التنفس،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من إنخفاض شديد في الضغط الشرياني (ضغط دم منخفض) ،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من تضيّق الصمام الأبهري (تضيّق أبهري) أو من صدمة قلبية (الحالة التي يعجز فيها القلب عن ضخ الكمية الكافية من الدم إلى الجسم)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من قصور قلبي تالي للإصابة بنوبة قلبية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من مرض خطير في الكلي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من مرض كبدي صارم أو إن كنت تشكو من اعتلال دماغي كبدي (مرض دماغي ناتج عن اعتلال كبدي)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من انخفاض نسبة البوتاسيوم في الدم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنتِ تُرضعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL">إذا انطبقت عليك إحدى الحالات التالية ، عليك مراجعة الطبيب قبل تناول ناتريكسام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية حديثة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من قصور في القلب، اضطرابات في نظم القلب، إن كنت تشكو من مرض الشريان التاجي (مرض القلب الناتج عن تدفق الدم غير الكافي في أوعية القلب)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من مشاكل كلوية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بضعف في النظر أو ألم في العين. قد تكون هذه أعراض تراكم السوائل في الطبقة الوعائية بالعين (الانصباب المشيمي) أو زيادة الضغط في عينك ويمكن أن تحدث خلال ساعات إلى أسبوع من تناول ناتريكسام. يمكن أن يؤدي هذا إلى فقدان الرؤية بصورة دائمة إذا لم يتم علاجه. إذا كنت قد أصبت من قبل بحساسية تجاه البنسلين أو سلفوناميد، يمكن أن تكون أكثر عرضة للإصابة بهذه الأعراض،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع شديد في الضغط الشريان (نوبة فرط الضغط)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مسنا وبحاجة إلى زيادة جرعتك،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تتناول أدوية أخرى،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من سوء التغذية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تشكو من مرض كبدي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصاباً بداء السكّري،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصاباً بالنقرس،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت ستخضع لفحص الغدة الدرقيّة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعرّضت لردود فعل حساسية تجاه الضوء.</p><p dir="RTL">يمكن للطبيب أن يصف لك فحوصات بيولوجية قصد مراقبة النسب المنخفضة من الصوديوم أو البوتاسيوم، أو النسب المرتفعة من الكالسيوم في الدم.</p><p dir="RTL">إن كنت تعتقد أنك معني بهذه الحالات أو إن كانت لديك أسئلة أخرى حول استعمال هذا الدواء، استشر الطبيب أو الصيدلاني.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون </strong></p><p dir="RTL">لا يجوز استعمال هذا الدواء لدى الأطفال والمراهقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وناتريكسام</strong><strong> </strong></p><p dir="RTL">عليك إبلاغ الطبيب أو الصيدلاني إن كنت تتناول أو تناولت مؤخراً أو ستتناول أدوية أخرى.</p><p dir="RTL"><strong>تجنّب</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>ناتريكسام:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مع الليثيوم (يستعمل لعلاج الاضطرابات العقلية مثل الهوس والهوس الاكتئابي والاكتئاب المتكرر) بسبب خطر زيادة نسبة الليثيوم في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مع دانترولين (حقن لمعالجة الارتفاع الخطير لدرجة حرارة الجسم).</p><p dir="RTL">يجب أن تُعلم طبيبك إن كنت تتناول أيًّا من الأدوية التالية، حيث يتوجب أخذ بعض الاحتياطات الخاصة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى مستعملة في علاج ارتفاع الضغط الشرياني،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مستعملة في علاج خلل نظم القلب (منها: كينيدين، هيدروكينيدين، ديزوبيراميد، أميودارون، سوتالول، إيبيتيليد، دوفيتيليد)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مستعملة في علاج الاضطرابات العقلية، كالإكتئاب، أو القلق، أو الفصام... (مثل : مضادات الاكتئاب الثلاثية الحلقات، أو مضادات الذهان، أو مضادات الذهان العصبي)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ببريديل b&eacute;pridil (المستعمل لمعالجة الذبحة الصدرية: مرض ينتج عنه آلام في الصدر)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سيزابريد cisapride، ديفيمانيل diph&eacute;manil (المستعمل لمعالجة الاضطرابات المعدية-المعوية)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سبارفلوكساسين sparfloxacine، موكسيفلوكساسين moxifloxacine، إريثروميسين عن طريق الحقن&eacute;rythromycine<strong> </strong>&nbsp;(مضادات حيويّة لمعالجة التعفن)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فينكامين IV (لعلاج اضطرابات الاستيعاب لدى المتقدمين بالسن ومنها فقدان الذاكرة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; هالوفانترين halofantrine (مضاد للطفيليات لعلاج بعض أنواع الملاريا)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; بنتاميدين pentamidine (لعلاج بعض أنواع داء الرئة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ميزولاستين mizolastine (لعلاج التفاعلات الحساسية مثل زكام الطلع)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيرويدية للتخفيف من الألم (مثال: إيبيبروفين ibuprof&egrave;ne) أو الأدوية المحتوية على مقدار كبير من الحمض الأسيتيلساليسيليكي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات خميرة التحويل (IEC) (المستعملة في علاج ارتفاع الضغط الشرياني والقصور القلبي)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الستيرويدات القشرية (corticost&eacute;ro&iuml;des) التي يتمّ تناولها عن طريق الفم لعلاجات اضطرابات مختلفة: منها الربو الحاد والتهاب المفصل الرثياني،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ديجيتاليك (digitaliques) (لعلاج أمراض القلب)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; المسهّلات المنبّهة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; باكلوفين baclof&egrave;ne (لعلاج تيبس العضلات الحاصل في أمراض مثل التصلب الصفائحي)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مدرّات البول المدخّرة للبوتاسيوم (أميلوريد، سبيرونولاكتون، تريامتيرين)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ميتفورمين metformine (لعلاج داء السكري)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; المواد الملوّنة باليود (المستعملة في فحوصات الأشعّة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حبّات الكالسيوم أو كماليّات الكالسيوم الأخرى،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كابتات المناعة (الادوية المستعملة في التحكم بالإجابة المناعية لجسمك من اجل علاج الأمراض الذاتيّة المناعة أو على إثر عمليّات غرس الأعضاء (مثل: سيكلوسبورين ciclosporine، تاكروليموس tacrolimus)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سيروليموس Sirolimus، تمسيروليموس temsirolimus، إيفيروليموس everolimus، وأدوية أخرى تنتمي لفئة كابحات mTOR (أدوية مستعملة لتعديل طريقة اشتغال النظام المناعي)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تيتراكوزاكتيد tetracosactide (لعلاج مرض كرون Crohn)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول k&eacute;toconasole، إيتراكونازول itraconazole، آمفوتيريسين amphot&eacute;ricine B بالحقن (لعلاج الإصابات الفطرية)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير ritonavir، إندينافيرindinavir ، نيلفنافيرnelfinavir &nbsp;(والتي تدعى مثبطات البروتياز والتي تستعمل في علاج فيروس نقص المناعة البشرية)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين rifampicine، إيريتروميسينerythromycine ، كلاريتروميسينclarithromycine &nbsp;(مضادات حيوية مستعملة لعلاج الإصابات العائدة للجراثيم)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <em>Hypericum</em> <em>perforatum</em> (نبتة الأوفاريقون) ،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميلv&eacute;rapamil ، ديلتيازيمdiltiazem &nbsp;(أدوية للقلب)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سيمفاستاتينsimvastatine &nbsp;(دواء يستعمل لتخفيض الكولسترول)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; آلوبورينول allopurinol (لعلاج النقرس).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ناتريكس</strong><strong>ام</strong><strong> </strong><strong>مع الطعام</strong><strong> </strong><strong>والشراب</strong></p><p dir="RTL">يجب عدم تناول البامبلوموس (الليمون الهندي) وعصيره من قبل الأفراد الذين يتناولون ناتريكسام، وذلك لأن البامبلوموس وعصيره قد يسببان ارتفاع تجمّع مادة الأملوديبين الفعالة في الدم، مما قد يسبب زيادة غير متوقعة في التأثير الخافض لضغط الدم لناتريكسام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">إذا كنتِ حاملا أو مرضعا، أو تعتقدين أنك ربما كنت حاملا، أو تخططين للحمل، فاطلبي نصيحة الطبيب أو الصيدلاني قبل تناول هذا الدواء.</p><p dir="RTL">لا يُنصح بتناول هذا الدواء طوال مدّة الحمل. فإن كان الحمل متُوقعاً أو إن ظهر الحمل، وجب اللجوء إلى علاج آخر بأسرع وقت ممكن.</p><p dir="RTL">لا يجب تناول ناتريكسام أثناء فترة الرضاعة. أخبري الطبيب فورا إن كنت ترضعين أو بصدد بداية الإرضاع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستخدام الآلات</strong></p><p dir="RTL">يمكن لناتريكسام أن يؤثر في قدرتك على قيادة السيارات واستخدام الالات. إذا كانت الأقراص تسبب لك الشعور بالدوخة أو الضعف أو التعب، أو تسبب لك الصداع، فيجب أن تتجنب القيادة أو استخدام الآلات وأن تراجع الطبيب على الفور. فإن حصل لك هذا، عليك تجنّب قيادة السيّارات أو القيام بأي نشاط يقتضي اليقظة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ناتريكس</strong><strong>ام</strong><strong> </strong><strong>يحتوي على لاكتوز أحادي الماء </strong></p><p dir="RTL">لا ينصح باستعمال هذا الدواء لدى المرضى المعانين من سوء تحمل الغلاكتوز، أو قصور كلي لمادة اللاكتاز، أو متلازمة عدم امتصاص الغلوكوز أو الغلاكتوز (أمراض وراثية نادرة). إذا أعلمك الطبيب أنك تعاني من سوء تحمل بعض أنواع السكر، عليك مراجعته قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ناتريكس</strong><strong>ام يحتوي على صوديوم </strong></p><p dir="RTL">ناتريكسام يحتوي على أقل من 1 ميلي مول من الصوديوم (23 ملغ في كل قرص، مما يعنى أنه بشكل رئيسي &laquo;خال من الصوديوم&raquo;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عند تناول هذا الدواء، يجب دائما التقيد بتعليمات الطبيب أو الصيدلاني. في حال الشك، استشر الطبيب أو الصيدلاني.</p><p dir="RTL">إن المقدار الموصى به هو قرص واحد مرة واحدة في اليوم، من الأفضل في الصباح.</p><p dir="RTL">يجب بلع القرص كاملا مع الماء دون مضغه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في</strong><strong> </strong><strong>حال</strong><strong> </strong><strong>تناولت من</strong><strong> </strong><strong>ناتريكسام </strong><strong>أكثر</strong><strong> </strong><strong>من</strong><strong> </strong><strong>اللازم</strong></p><p dir="RTL">استشر الطبيب أو الصيدلاني على الفور.</p><p dir="RTL">إن تناول الكثير من الأقراص يمكن أن ينتج عنه في بعض الأحيان انخفاض خطير في الضغط الشرياني. قد تشعر بدوخة، نعاس، فقدان الوعي أو الإحساس بالضعف. قد تتعرّض للغثيان، للقيء، لتشنجات عضلية، لحالة ارتباك وتغيرات في كمية البول الذي تنتجه الكلي. يمكن حدوث صدمة إذا انخفض الضغط الشرياني بشكل صارم. أيضا سوف يصبح جلدك باردا ورطبا ويمكن أن تفقد الوعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في</strong><strong> </strong><strong>حال</strong><strong> </strong><strong>سهوت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>ناتريكسام </strong></p><p dir="RTL">لا تقلق. إن سهوت عن تناول قرص، تناول الجرعة التالية في اليوم التالي حسب الوتيرة الاعتيادية.</p><p dir="RTL">لا تتناول جرعة مزدوجة للتعويض عن الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال التوقف عن تناول ناتريكسام </strong></p><p dir="RTL">إن علاج ارتفاع الضغط الشرياني هو عموما علاج طويل الأمد، عليك استشارة الطبيب قبل التوقّف عن تناول هذا الدواء.</p><p dir="RTL">إن كانت لديك أسئلة أخرى حول استعمال هذا الدواء، اطلب المزيد من المعلومات من الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1-&nbsp;&nbsp;&nbsp; </strong><strong>ماهي</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبيّة</strong><strong> </strong><strong>المحتملة</strong><strong>؟</strong><strong> </strong></p><p dir="RTL">كما هو الحال مع كل دواء، قد تنتج عن هذا الدواء آثار جانبيّة، علما بأنها لا تحصل بالضرورة لدى جميع الأشخاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا لاحظت حدوث أي من التأثيرات الجانبية المذكورة فيما يلي، عليك أن تتوقف حالا عن تناول</strong><strong> هذا</strong><strong> </strong><strong>الدواء، وأن تتصل بالطبيب على الفور</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ الجفون أو الوجه أو الشفاه (نادر جدا، يمكن أن يصيب شخصا واحدا من أصل 10.000 شخص)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تضخم في اللسان وفي الحلق مما يسبب صعوبة شديدة في التنفس (نادر جدا، يمكن أن يصيب شخصا واحدا من أصل 10.000 شخص)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية صارمة، خاصة الطفح الجلدي الشديد، الشرى، احمرار الجلد المنتشر في جميع أنحاء الجسم، حكة شديدة، ظهور حويصلات، تقشر الجلد وتورمه، التهاب الأغشية المخاطية (متلازمة ستيفنس جونسون، التسمّم الجلدي &nbsp;الصارم) أو غير ذلك من التفاعلات التحسسية (نادر جدا، يمكن أن يصيب شخصا واحدا من أصل 10.000 شخص)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية (نادر جدا، يمكن أن يصيب شخصا واحدا من أصل 10.000 شخص)، خفقان القلب غير المنتظم والذي قد يطرح مسألة التشخيص الحيوي )لولبة الأطراف) (تواتر غير محدّد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; خفقان القلب غير الطبيعي (قليل التواتر، يمكن أن يصيب شخصا واحدا من أصل 100 شخص)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس الذي قد يؤدي إلى آلام شديدة في البطن والظهر مع شعور بالإعياء الشديد (نادر جدا، يمكن أن يصيب شخصا واحدا من أصل 10.000 شخص)؛</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن حدوث التأثيرات الجانبية الشائعة التالية. إذا كان أيا منها قد سبب لك ازعاجا أو استمر لمدة تتجاوز الأسبوع الواحد، فيجب مراجعة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جد شائعة (قد تصيب اكثر من شخص من أصل 10</strong><strong> أشخاص</strong><strong>):</strong></p><p dir="RTL">&nbsp;- وذمة (احتباس الماء).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات شائعة</strong><strong> </strong><strong>(</strong><strong>قد تصيبب</strong><strong> </strong><strong>حتى</strong><strong> </strong><strong>شخص واحد من أصل 10 أشخاص</strong><strong>):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صداع، دوخة، نعاس (خاصة في بداية العلاج)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بصرية، رؤية مزدوجة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اختلاجات (الإحساس بخفقان القلب)، فورة أو احمرار (الإحساس بحرارة في الوجه)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن، إحساس بوعكة (غثيان)، اضطرابات معويّة، إسهال، إمساك، عسر الهضم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تورم الكاحلين، عياء، ضعف، تشنجات عضلية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة البوتاسيوم في الدم الذي قد يسبب وهنا عضليا؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تمّ الإبلاغ بالتأثيرات الجانبية الأخرى الواردة في القائمة أدناه. إذا تفاقمت شدة أي منها، أو إذا لاحظت ظهور أي تأثيرات جانبية لم يرد ذكرها في هذه النشرة، عليك إبلاغ الطبيب أو الصيدلاني عنها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تاثيرات شائعة قليلا</strong><strong> </strong><strong>(</strong><strong>قد تصيبب</strong><strong> </strong><strong>حتى</strong><strong> </strong><strong>شخص واحد من أصل 100 شخص</strong><strong>):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في المزاج، قلق، اكتئاب، أرق؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; رجفان؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; خلل في الذوق؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالتخدّر أو تنمّل في الأعضاء، فقدان الإحساس بالألم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; رنين أو طنين في الأذنين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الضغط الشرياني؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عطس وسيلان الأنف ناتجان عن التهاب الغشاء المخاطي للأنف (التهاب مخاطية الأنف)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سعال، جفاف الفم، تقيؤ (غثيان)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر، زيادة التعرق، حكاك جلدي، بقع حمراء على الجلد، تغير لون الجلد، شرى؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التبول، زيادة الرغبة في التبول ليلا، زيادة عدد مرات التبول؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عجز الانتصاب الجنسي، اضطراب أو تضخّم الثدي لدى الرجل؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم، وعكة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل أو العضلات، ألم في الظهر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة أو نقصان في الوزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات نادرة</strong><strong> </strong><strong>(قد تصيب أقل من شخص واحد من أصل 1.000 شخص)</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حالة ارتباك؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالدوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات </strong><strong>نادرة</strong><strong> </strong><strong>جداً</strong><strong> (</strong><strong>قد تصيب أقل من شخص واحد من أصل 10.000 شخص)</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تغيّرات في صيغة الدم مثل قلّة الصفيحات (انخفاض عدد الصفيحات المؤدي إلى زراق أو نزيف من الأنف)، قلة الكريات البيضاء (انخفاض عدد كريات البيضاء المؤدي إلى حمّى غير مبرّرة، أو تهيّج في الحلق، أو عوارض أخرى للنزلة الصدرية &ndash; فإن حدث لك هذا يجب مراجعة الطبيب)، &nbsp;فقر الدم (انخفاض عدد الكريات الحمراء)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مقدار السكر في الدم (فرط سكر الدم)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إرتفاع معدل الكالسيوم في الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في الأعصاب تسبب الضعف أول التنمل أو التخدّر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ اللثة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ في البطن (التهاب المعدة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الوظيفة الكبدية، التهاب الكبد، اصفرار الجلد (اليرقان)، ارتفاع معدل الأنزيمات الكبدية مما يؤثر على بعض التحاليل الطبية. في حالة القصور الكبدي، يمكن أن يحدث اعتلال دماغي كبدي (داء تنكّس الدماغ الناتج عن اعتلال كبدي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مرض الكلي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الضغط العضلي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية المصاحبة غالبا بطفح جلدي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حساسية للضوء؛</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات ذات تواتر غير محدّد (عدم توفر معطيات كافية لتحديد التواتر) :</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يُحتمل ظهور تغيّرات في مقاييسك الحيوية، مما يدفع الطبيب إلى إجراء بعض التحاليل المخبريّة لدمك للتحكّم بها. التغيّرات التي قد تحصل هي التالية:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض معدّل الصوديوم في الدم قد ينتج عنه تجفّف في البدن وهبوط الضغط الشرياني،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع معدّل حمض اليوريك الذي يمكن أن يتسبب أو يزيد في تفاقم نوبات النقرس (ألم في المفاصل خاصة على مستوى القدم)،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرتفاع معدل الغلوكوز في الدم لدى المصابين بداء السكري،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تخطيط بياني كهربائي غير طبيعي للقلب،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; رؤية ضبابية عن بعد (قصر النظر)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; رؤية مشوشة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ضعف في النظر أو ألم في العين نتيجة ارتفاع الضغط (علامات محتملة لتراكم السوائل في الطبقة الوعائية بالعين (الانصباب المشيمي) أو الزرق مغلق الزاوية الحاد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; رجفان، وضعية صلبة، تعابير وجه جامدة، حركات بطيئة، سير بطيء غير متوازن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من قرّاض حُمامي منتشر (مرض الكولاجين)، فإنه قد يتفاقم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا أحسست بأي من الآثار الجانبية، عليك مراجعة الطبيب أو الصيدلاني. هذا يشمل أي آثار جانبية ممكنة لم يرد ذكرها في هذه النشرة. يمكنك أيضا الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق نظام الإبلاغ الوطني:</p><p dir="RTL">عند إبلاغك عن التأثيرات الجانبية فأنت تساهم في تقديم مزيد من المعلومات عن سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لاتترك هذا الدواء في متناول الأطفال أو تحت أنظارهم.</p><p dir="RTL">لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المبيّن على العبوة. تاريخ انتهاء الصلاحية هو آخر يوم من الشهر المشار إليه.</p><p dir="RTL">يحفظ في درجة حرارة لا تتعدى 30 درجة مئوية.</p><p dir="RTL">لا ترم أي دواء في المجارير العامة أو مع النفايات المنزلية. اطلب من الصيدلاني التخلص من الأدوية التي لم تعد تستعملها. ستساهم هذه الإجراءات في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما يحتوي عليه</strong><strong> </strong><strong>ناتريكسام </strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </strong>المادتان الفعّالتان هما: إنداباميد و أملوديبين<strong>.</strong></p><p dir="RTL">- ناتريكسام 1,5 ملغم/ 5 ملغم: حبة تحتوي على 1,5 ملغم من إنداباميد و 6,935 ملغم من بيسلات الأملوديبين المعادلة ل5 ملغم أملوديبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">- ناتريكسام 1,5 ملغم/ 10 ملغم: حبة تحتوي على 1,5 ملغم من إنداباميد و 13,87 ملغم من بيسلات الأملوديبين المعادلة ل10 ملغم أملوديبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي :</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>في نواة حبة ناتريكسام 1,5 ملغم</u><u>/</u><u> 5 ملغم:</u> لاكتوز أحادي الماء ، هيبروميلوز (E464)، ستيارات المغنيزيوم (E572)، بوفيدون (E1201)، سيليكا غروانية لامائية، هيدروجينوفسفات الكالسيوم الثنائي الماء، سلولوز ميكروكريستالين (E460)، كروسكارميلوز صودي (E468)، نشاء ذرة جيلاتيني.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في غشاء تلبيس قرص ناتريكسام 1,5&nbsp; ملغ/ 5 ملغ : غليسيرول (E422)، هيبروملوز (E464)، ماكروغول 6000، ستيارات المغنيزيوم (E572)، ثاني أكسيد التيتانيوم (E171).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>في غشاء التلبيس:</u> غليسيرول (E422)، هيبروميلوز (E464)، ماكروغول 6000، ستيارات المغنيزيوم (E572)، ثاني أكسيد التيتان (E171).</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>في نواة حبة ناتريكسام 1,5 ملغم</u><u>/</u><u> </u><u>10 ملغم:</u> لاكتوز أحادي الماء ، هيبروميلوز (E464)، ستيارات المغنيزيوم (E572)، بوفيدون (E1201)، سيليكا غروانية لامائية، هيدروجينوفسفات الكالسيوم الثنائي الماء، سلولوز ميكروكريستالين (E460)، كروسكارميلوز صودي (E468)، نشاء ذرة جيلاتيني.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>في غشاء التلبيس:</u> غليسيرول (E422)، هيبروميلوز (E464)، أكسيد الحديد الأحمر (E172)، ماكروغول 6000، ستيارات المغنيزيوم (E572)، ثاني أكسيد التيتان (E171).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>ما هو&nbsp; ناتريكسام </strong><strong>وما هو محتوى التغليف الخارجي</strong><strong>؟</strong></p><p dir="RTL"><u>ناتريكسام 1,5 ملغم</u><u>/</u><u> </u><u>5 ملغم:</u></p><p dir="RTL">أقراص ناتريكسام بيضاء اللون، مستديرة الشكل، ملبسة، ذات تحرير معدل، بقطر 9 ملم منقوش بعلامة <strong><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:16.8pt;
 height:9pt'>
 <v:imagedata src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="" cropbottom="16701f"/>
</v:shape><![endif]--><img width="22" height="12" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;على إحدى الجهتين.</p><p dir="RTL">الأقراص متوفرة في صفائح تحتوي على 15 و 30 و 60 و90 قرصا وفي علب أقراص تحتوي&nbsp; على 100 و 500 قرص.</p><p dir="RTL">هذه الأشكال ليست كلها مسوّقة.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>ناتريكسام 1,5 ملغم</u><u>/</u><u> </u><u>10 ملغم:</u></p><p dir="RTL">أقراص ناتريكسام وردية اللون، مستديرة الشكل، ملبسة، ذات تحرير معدل، بقطر 9 ملم منقوش بعلامة<!--[if gte vml 1]><v:shape id="Image_x0020_1" o:spid="_x0000_i1026"
 type="#_x0000_t75" style='width:17.4pt;height:9pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title="" cropbottom="16701f"/>
</v:shape><![endif]--><img width="23" height="12" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /> على إحدى الجهتين.</p><p dir="RTL">الأقراص متوفرة في صفائح تحتوي على 15 و 30 و 60 و90 قرصا وفي علب أقراص تحتوي&nbsp; على 100 و 500 قرص.</p><p dir="RTL">هذه الأشكال ليست كلها مسوّقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اسم حامل رخصة التسويق</p><p dir="RTL"><strong>Les Laboratoires Servier</strong></p><p dir="RTL"><strong>50, rue Carnot</strong></p><p dir="RTL"><strong>92284 Suresnes cedex</strong></p><p dir="RTL"><strong>France</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">الجهة المصنعة</p><p dir="RTL"><strong>Les Laboratoires Servier Industrie</strong></p><p dir="RTL"><strong>905, route de Saran</strong></p><p dir="RTL"><strong>45520 Gidy</strong></p><p dir="RTL"><strong>France</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">للحصول على أي معلومات تتعلق بهذا الدواء، الرجاء الاتصال بالوكيل المحلي للجهة الحاملة لإجازة التسويق.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:581px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المملكة العربية السعودية</strong></p><p dir="RTL">المكتب العلمي لشركة سيرفير العربية السعودية</p><p dir="RTL">3533 السليمانية ، حي حطين، مكتب 101</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">هاتف: ٩٦٦١١2522330+</p><p dir="RTL">البريد الالكتروني: regulatory.sa1@servier.com</p></td><td style="vertical-align:top"><p dir="RTL"><strong>بلدان الخليج</strong></p><p dir="RTL">المكتب العلمي لمختبرات سيرفييه</p><p dir="RTL">ص.ب. ١٥٨٦، الطابق 15، برج أرينكو، مدينة دبي الإعلامية</p><p dir="RTL">طريق الشيخ زايد، دبي، الإمارات العربية المتحدة</p><p dir="RTL">هاتف: ٩٧١٤٣٣٢٩٩٠٣+</p><p dir="RTL">البريد الالكتروني: magdy.abdou@servier.com</p><p dir="RTL"><strong>&nbsp;</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;للإبلاغ عن التأثير(ات) الجانبية:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>-</strong><strong> المركز الوطني للتيقظ الدوائي</strong><strong> (NPC)</strong></p><p dir="RTL">- للاتصال بالرقم الموحد للهيئة العامة للغذاء والدواء 19999</p><p dir="RTL">- البريد الالكتروني:<strong> </strong>npc.drug@sfda.gov.sa</p><p dir="RTL">- الموقع الالكتروني: https://ade.sfda.gov.sa/<u> </u></p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><ul><li dir="RTL"><strong>دول الخليج العربي الأخرى:</strong></li></ul><p dir="RTL">- الرجاء الاتصال بالسلطات المختصة ذات الصلة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;مجلس وزراء الصحة العرب:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>إن هذا لدواء</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الدواء مستحضر يؤثر على صحّتك، وإستهلاكه خلافاً للتعليمات يعرّضك للخطر.</p><p dir="RTL">تقيّد بوصفة الطبيب، وبطريقة الإستعمال المنصوصة، وبتعليمات الصيدلاني الذي صرّف لك الدواء.</p><ul><li dir="RTL">فالطبيب والصيدلاني هما الخبيران بالدواء ونفعه وضرره.</li><li dir="RTL">لا تقطع مدة العلاج المحدّدة لك من تلقاء نفسك.</li><li dir="RTL">لا تكرر الوصفة دون مراجعة طبيبك.</li><li dir="RTL">احتفظ بكافة الأدوية بعبدا عن متناول أيدي الأطفال.</li></ul></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>مجلس وزراء الصحّة العرب</strong></p><p dir="RTL"><strong>وإتّحاد الصيادلة العرب</strong></p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;هذه النشرة لمعلومات المريض حائزة على موافقة الهيئة العامة للغذاء والدواء في المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04-2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Natrixam 1.5 mg / 5 mg modified-release tablets 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Indapamide	1.5 mg
Amlodipine	5 mg
Equivalent to amlodipine besilate	6.935 mg
For one tablet

Excipient with known effect: each tablet contains 104.5 mg lactose monohydrate
For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Modified-release tablet.
White, round, film-coated, bilayered, modified-release tablet of 9 mm diameter engraved with  on one face.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Natrixam is indicated as substitution therapy for treatment of essential hypertension in patients already controlled with indapamide and amlodipine given concurrently at the same dose level.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>One tablet per day as single dose, preferably to be taken in the morning, to be swallowed whole with water and not chewed.</p><p>The fixed dose combination is not suitable for initiation therapy.</p><p>If a change of the posology is required, titration should be done with the individual components.</p><p><strong>&nbsp;</strong></p><p><strong><u>Special populations</u></strong></p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of Natrixam in children and adolescents have not been established.</p><p>No data are available.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><em><u>Patients with renal impairment (see sections 4.3 and 4.4):</u></em></p><p>In severe renal impairment (creatinine clearance below 30 ml/min), treatment is contraindicated.</p><p>In patients with mild to moderate renal impairment, no dose adjustment is needed.</p><p>&nbsp;</p><p><em><u>Older people (see section 4.4 and 5.2):</u></em></p><p>Older people can be treated with Natrixam according to renal function.</p><p>&nbsp;</p><p><em><u>Patients with hepatic impairment (see sections 4.3 and 4.4):</u></em></p><p>In severe hepatic impairment, treatment is contraindicated.</p><p>Dosage recommendations of amlodipine have not been established in patients with mild to moderate hepatic impairment; therefore, dose selection should be cautious and should start at the lower end of the dosing range (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><strong><u>Method of administration </u></strong></p><p>Oral administration.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substances, to other sulfonamides, to dihydropyridine derivatives or to any of the excipients listed in section 6.1
•	Severe renal failure (creatinine clearance below 30 ml/min)
•	Hepatic encephalopathy or severe impairment of liver function
•	Hypokalaemia
•	Lactation
•	Severe hypotension
•	Shock (including cardiogenic shock)
•	Obstruction of the outflow tract of the left ventricle (e.g., high grade aortic stenosis)
•	Haemodynamically unstable heart failure after acute myocardial infarction

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Special warnings</u></strong></p><p><em>Hepatic encephalopathy:</em></p><p>When liver function is impaired, thiazide-related diuretics may cause hepatic encephalopathy, particularly in case of electrolyte imbalance. Due to the presence of indapamide, administration of Natrixam must be stopped immediately if this occurs.<br />&nbsp;</p><p><em>Photosensitivity:</em></p><p>Cases of photosensitivity reactions have been reported with thiazides and thiazide-related diuretics (see section 4.8). If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a re-administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.</p><p><strong>&nbsp;</strong></p><p><strong><em><u>Precautions for use</u></em></strong></p><p><em>Hypertensive crisis:</em></p><p>The safety and efficacy of amlodipine in hypertensive crisis have not been established.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Water and electrolyte balance:</em></p><p><em>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Plasma sodium:</p><p>This must be measured before starting treatment, then at regular intervals subsequently. The fall in plasma sodium may be asymptomatic initially and regular monitoring is therefore essential, and should be even more frequent in the elderly and cirrhotic patients (see sections 4.8 and 4.9).</p><p>Any diuretic treatment may cause hyponatraemia, sometimes with very serious consequences. Hyponatraemia with hypovolaemia may be responsible of dehydration and orthostatic hypotension. Concomitant loss of chloride ions may lead to secondary compensatory metabolic alkalosis: the incidence and degree of this effect are slight.</p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plasma potassium:</p><p>Potassium depletion with hypokalaemia is the major risk of thiazide and related diuretics.&nbsp; The risk of onset of hypokalaemia (&lt; 3.4 mmol/l) must be prevented in certain high risk populations, i.e. the elderly, malnourished and/or polymedicated, cirrhotic patients with oedema and ascites, coronary artery disease and cardiac failure patients. In this situation, hypokalaemia increases the cardiac toxicity of digitalis preparations and the risks of arrhythmias.</p><p><strong><em>&nbsp;</em></strong></p><p>Individuals with a long QT interval are also at risk, whether the origin is congenital or iatrogenic. Hypokalaemia, as well as bradycardia, is then a predisposing factor to the onset of severe arrhythmias, in particular, potentially fatal torsades de pointes.</p><p>&nbsp;</p><p>More frequent monitoring of plasma potassium is required in all the situations indicated above. The first measurement of plasma potassium should be obtained during the first week following the start of treatment.</p><p>Detection of hypokalaemia requires its correction.</p><p>&nbsp;</p><p>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plasma calcium:</p><p>Thiazide and related diuretics may decrease urinary calcium excretion and cause a slight and transitory rise in plasma calcium. Frank hypercalcaemia may be due to previously unrecognised hyperparathyroidism. Treatment should be withdrawn before the investigation of parathyroid function.</p><p><strong><em>&nbsp;</em></strong></p><p><em>Blood glucose:</em></p><p>Due to the presence of indapamide, monitoring of blood glucose is important in diabetics, in particular in the presence of hypokalaemia.</p><p><strong>&nbsp;</strong></p><p><em>Cardiac failure:</em></p><p>Patients with heart failure should be treated with caution. In a long-term, placebo controlled study in patients with severe heart failure (NYHA class III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine treated group than in the placebo group.</p><p>Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.</p><p><strong>&nbsp;</strong></p><p><em>Renal function:</em></p><p>Thiazide and related diuretics are fully effective only when renal function is normal or only minimally impaired (plasma creatinine below levels of the order of 25 mg/l, i.e. 220 &micro;mol/l in an adult). In the elderly, this plasma creatinine must be adjusted in relation to age, weight and gender.</p><p>&nbsp;</p><p>Hypovolaemia, secondary to the loss of water and sodium induced by the diuretic at the start of treatment causes a reduction in glomerular filtration. This may lead to an increase in blood urea and plasma creatinine. This transitory functional renal insufficiency is of no consequence in individuals with normal renal function but may worsen preexisting renal insufficiency.</p><p><strong>&nbsp;</strong></p><p>Amlodipine may be used in patients with renal failure at normal doses. Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment. Amlodipine is not dialysable.</p><p>&nbsp;</p><p>The effect of the combination Natrixam has not been tested in renal dysfunction. In renal impairment, Natrixam doses should respect those of the individual components taken individually.</p><p><strong>&nbsp;</strong></p><p><em>Uric acid:</em></p><p>Due to the presence of indapamide, tendency to gout attacks may be increased in hyperuricaemic patients.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Hepatic function:</em></p><p>The half-life of amlodipine is prolonged and Area Under the Curve (AUC) values are higher in patients with impaired liver function. Dosage recommendations have not been established. Amlodipine should therefore be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the dose.</p><p><strong><u>&nbsp;</u></strong></p><p>The effect of the combination Natrixam has not been tested in hepatic dysfunction. Taking into account the effect of indapamide and amlodipine, Natrixam is contra-indicated in patients with severe hepatic impairment, and caution should be exercised in patients with mild to moderate hepatic impairment.</p><p>&nbsp;</p><p><em>Choroidal effusion, acute myopia and secondary angle-closure glaucoma</em></p><p>Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Older people</em></p><p>Older patients can be treated with Natrixam according to renal function (see sections 4.2 and 5.2).</p><p><strong><u>&nbsp;</u></strong></p><p><em>Excipients:</em></p><p>This medicinal product contains lactose. Its use is not recommended in patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.</p><p>&nbsp;</p><p><em>Level of sodium</em></p><p>Natrixam contains less than 1 mmol sodium (23 mg) per tablet, i.e. essentially &lsquo;sodium-free&rsquo;.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>LINKED TO INDAPAMIDE:</u></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><u>Combinations that are not recommended:</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lithium</strong></p><p>Increased plasma lithium with signs of overdose, as with a salt-free diet (decreased urinary lithium excretion). However, if the use of diuretics is necessary, careful monitoring of plasma lithium and dose adjustment are required.</p><p><strong>&nbsp;</strong></p><p><strong><u>Combinations requiring precautions for use:</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Torsades de pointes-inducing medicines</strong></p><p>o&nbsp;&nbsp; Class Ia antiarrhythmics (quinidine, hydroquinidine, disopyramide).</p><p>o&nbsp;&nbsp; Class III antiarrhythmics (amiodarone, sotalol, dofetilide, ibutilide).</p><p>o&nbsp;&nbsp; Some antipsychotics:</p><p>Phenothiazines&nbsp;(chlorpromazine, cyamemazine, levomepromazine, thioridazine, trifluoperazine).</p><p>Benzamides (amisulpride, sulpiride, sultopride, tiapride).</p><p>Butyrophenones (droperidol, haloperidol).</p><p>Others: bepridil, cisapride, diphemanil, erythromycin IV, halofantrine, mizolastine, pentamidine, sparfloxacin, moxifloxacin, vincamine IV.</p><p>Increased risk of ventricular arrhythmias, particularly <em>torsades de pointes </em>(hypokalaemia is a risk factor).</p><p>Monitor for hypokalaemia and correct, if required, before introducing this combination.<strong> </strong>Clinical, plasma electrolytes and ECG monitoring.</p><p><em>Use substances which do not have the disadvantage of causing torsades de pointes in the presence of hypokalaemia</em><em>.</em></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>N.S.A.I.Ds. (systemic route) including COX-2 selective inhibitors, high dose acetylsalicylic acid (</strong>&sup3;<strong>&nbsp;3</strong><strong>&nbsp;g/day)</strong></p><p>Possible reduction in the antihypertensive effect of indapamide.</p><p>Risk of acute renal failure in dehydrated patients (decreased glomerular filtration).&nbsp;</p><p>Hydrate the patient; monitor renal function at the start of treatment.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Angiotensin converting enzyme (A.C.E.) inhibitors</strong></p><p>Risk of sudden hypotension and/or acute renal failure when treatment with an A.C.E. is initiated in the presence of preexisting sodium depletion (particularly in patients with renal artery stenosis).</p><p><strong>&nbsp;</strong></p><p><em>In essential hypertension</em>, when prior diuretic treatment may have caused sodium depletion, it is necessary:</p><p>o&nbsp;&nbsp; either to stop the diuretic 3 days before starting treatment with the A.C.E. inhibitor, and restart a hypokalaemic diuretic if necessary;</p><p>o&nbsp;&nbsp; or give low initial doses of the A.C.E. inhibitor and increase the dose gradually.</p><p>&nbsp;</p><p><em>In congestive heart failure</em>, start with a very low dose of A.C.E. inhibitor, possibly after a reduction in the dose of the concomitant hypokalaemic diuretic.</p><p><em>In all cases</em>, monitor renal function (plasma creatinine concentration) during the first weeks of treatment with an A.C.E. inhibitor.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other compounds causing hypokalaemia: amphotericin B (IV), gluco- and mineralo-corticoids (systemic route), tetracosactide, stimulant laxatives</strong></p><p>Increased risk of hypokalaemia (additive effect).</p><p>Monitoring of plasma potassium and correction if required. Must be particularly borne in mind in case of concomitant digitalis treatment. Use non-stimulant laxatives.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Digitalis preparations</strong></p><p>Hypokalaemia predisposing to the toxic effects of digitalis.</p><p>Monitoring of plasma potassium and ECG and, if necessary, adjust the treatment.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Baclofen</strong></p><p>Increased antihypertensive effect.</p><p>Hydrate the patient; monitor renal function at the start of treatment.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Allopurinol</strong></p><p>Concomitant treatment with indapamide may increase the incidence of hypersensitivity reactions to allopurinol.</p><p><strong>&nbsp;</strong></p><p><strong><u>Combinations to be taken into consideration:</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Potassium-sparing diuretics (amiloride, spironolactone, triamterene)</strong></p><p>Whilst rational combinations are useful in some patients, hypokalaemia or hyperkalaemia (particularly in patients with renal failure or diabetes) may still occur. Plasma potassium and ECG should be monitored and, if necessary, treatment reviewed.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Metformin</strong></p><p>Increased risk of metformin induced lactic acidosis due to the possibility of functional renal failure associated with diuretics and more particularly with loop diuretics.</p><p>Do not use metformin when plasma creatinine exceeds 15 mg/l (135&nbsp;&micro;mol/l) in men and 12 mg/l (110&nbsp;&micro;mol/l) in women.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Iodinated contrast media</strong></p><p>In the presence of dehydration caused by diuretics, increased risk of acute renal failure, in particular when large doses of iodinated contrast media are used.</p><p>Rehydration before administration of the iodinated compound.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Imipramine-like antidepressants (tricyclic), neuroleptics</strong></p><p>Antihypertensive effect and increased risk of orthostatic hypotension increased (additive effect).</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Calcium (salts)</strong></p><p>Risk of hypercalcaemia resulting from decreased urinary elimination of calcium.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Ciclosporine, tacrolimus</strong></p><p>Risk of increased plasma creatinine without any change in circulating ciclosporine levels, even in the absence of water/sodium depletion.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Corticosteroids, tetracosactide (systemic route)</strong></p><p>Decreased antihypertensive effect (water/sodium retention due to corticosteroids).</p><p><strong>&nbsp;</strong></p><p><strong><u>LINKED TO AMLODIPINE</u></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><u>Dantrolene (infusion):</u> In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</p><p><strong>&nbsp;</strong></p><p><u>Administration of amlodipine with grapefruit or grapefruit juice</u><strong> </strong>is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><u>CYP3A4 inhibitors:</u><strong> </strong>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</p><p>&nbsp;</p><p>There is an increased risk of hypotension in patients receiving clarithromycin with amlodipine. Close observation of patients is recommended when amlodipine is co administered with clarithromycin.</p><p>&nbsp;</p><p><u>CYP3A4 inducers:</u> Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine may vary. &nbsp;Therefore, blood pressure should be monitored and dose regulation considered both during and after concomitant medication particularly with strong CYP3A4 inducers (e.g. rifampicin, <em>hypericum perforatum</em>).</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><u>Effects of amlodipine on other medicinal products:</u></p><p>The blood pressure lowering effects of amlodipine adds to the blood pressure-lowering effects of other medicinal products with antihypertensive properties.</p><p>&nbsp;</p><p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin or warfarin.</p><p>&nbsp;</p><p><u>Tacrolimus:</u><strong> </strong>There is a risk of increased tacrolimus blood levels when co administered with amlodipine. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.<strong> </strong></p><p><strong>&nbsp;</strong></p><p><u>Mechanistic Target of Rapamycin (mTOR) Inhibitors:</u> mTOR inhibitors such as sirolimus, temsirolimus, and everolimus are CYP3A substrates. Amlodipine is a weak CYP3A inhibitor. With concomitant use of mTOR inhibitors, amlodipine may increase exposure of mTOR inhibitors.</p><p><u>Ciclosporine:</u><strong> </strong>No drug interaction studies have been conducted with ciclosporine and amlodipine in healthy volunteers or other populations with the exception of renal transplant patients, where variable trough concentration increases (average 0% - 40%) of ciclosporine were observed. Consideration should be given to monitoring ciclosporine levels in renal transplant patients on amlodipine, and ciclosporine dose reductions should be made as necessary.</p><p><strong>&nbsp;</strong></p><p><u>Simvastatin:</u><strong> </strong>Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin to 20 mg daily in patients on amlodipine.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given the effects of the individual components in this combination product on pregnancy and lactation:</p><p>Natrixam is not recommended during pregnancy.</p><p>Natrixam is contra-indicated during lactation.</p><p><strong>&nbsp;</strong></p><p><strong><u>Pregnancy</u></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><u>LINKED TO INDAPAMIDE</u></strong></p><p>There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of indapamide in pregnant women. Prolonged exposure to thiazide diuretics during the third trimester of pregnancy can reduce maternal plasma volume as well as uteroplacental blood flow, which may cause a foeto-placental ischaemia and growth retardation (intra-uterine). Moreover, rare cases of hypoglycaemia and thrombocytopenia in neonates have been reported following exposure near term.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><u>LINKED TO AMLODIPINE</u></strong></p><p>The safety of amlodipine in human pregnancy has not been established.</p><p>In animal studies, reproductive toxicity was observed at high doses (see section 5.3).</p><p><strong>&nbsp;</strong></p><p><strong><u>Breastfeeding</u></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><u>LINKED TO INDAPAMIDE</u></strong></p><p>There is insufficient information on the excretion of indapamide/metabolites in human milk. Hypersensitivity to sulfonamide-derived medicines and hypokalaemia might occur. A risk to the newborns/infants cannot be excluded.</p><p>Indapamide is closely related to thiazide diuretics which have been associated, during breast-feeding, with a decrease or even suppression of milk lactation.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>LINKED TO AMLODIPINE</u></strong></p><p>Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3 &ndash; 7%, with a maximum of 15%. The effect of amlodipine on infants is unknown.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Fertility</u></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><u>LINKED TO INDAPAMIDE</u></strong></p><p>Reproductive toxicity studies showed no effect on fertility in female and male rats (see section 5.3). No effects on human fertility are anticipated.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><u>LINKED TO AMLODIPINE</u></strong></p><p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse reactions were found on male fertility (see section 5.3).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Natrixam has minor or moderate influence on the ability to drive and use machines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Indapamide does not affect vigilance but different reactions in relation with the decrease in blood pressure may occur in individual cases, especially at the start of the treatment or when another antihypertensive agent is added. As a result the ability to drive vehicles or to operate machinery may be impaired.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amlodipine can have minor or moderate influence on the ability to drive and use machines. If patients taking amlodipine suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired. Caution is recommended especially at the start of treatment.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Summary of the safety profile </u></strong></p><p>The most commonly reported adverse reactions with indapamide and amlodipine given separately are hypokalaemia, somnolence, dizziness, headache, visual impairment, diplopia, palpitations, flushing, dyspnoea, abdominal pain, nausea, dyspepsia, change of bowel habit, diarrhoea, constipation, rash maculo-papular, ankle swelling, muscle spasms, oedema, fatigue and asthenia.</p><p><strong>&nbsp;</strong></p><p><strong><u>Tabulated list of adverse reactions </u></strong></p><p>The following adverse reactions have been observed and reported during treatment with indapamide and amlodipine with the following frequencies: Very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &le; 1/100); rare (&ge; 1/10,000 to &le; 1/1,000); very rare (&le; 1/10,000); not known (cannot be estimated from the available data).</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>MedDRA</strong></p><p><strong>System organ class</strong></p></td><td rowspan="2"><p><strong>Adverse reactions</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Indapamide</strong></p></td><td style="vertical-align:top"><p><strong>Amlodipine</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Agranulocytosis</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Aplastic anaemia</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p><p>-</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>Common</p><p>During clinical studies, hypokalaemia (plasma potassium &lt; 3.4 mmol/l) was seen in 10 % of patients and &lt; 3.2 mmol/l in 4 % of patients after 4 to 6 weeks treatment. After 12 weeks treatment, the mean fall in plasma potassium was 0.23&nbsp;mmol/l.</p><p>(see section 4.4).</p></td><td style="vertical-align:top"><p>-</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypercalcaemia</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatraemia with hypovolaemia*</p></td><td style="vertical-align:top"><p>Not known</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Mood altered (including anxiety)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Confusional state</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="12" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common (especially at the beginning of the treatment)</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common (especially at the beginning of the treatment)</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Common (especially at the beginning of the treatment)</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hypoaesthesia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hypertonia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Neuropathy peripheral</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Extrapyramidal disorder (extrapyramidal syndrome)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Possibility of onset of hepatic encephalopathy&nbsp; in case of hepatic insufficiency</p></td><td style="vertical-align:top"><p>Not known (see sections 4.3 and 4.4)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Visual impairment</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Diplopia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td><p>Myopia</p></td><td style="vertical-align:top"><p>Not known</p></td><td><p>-</p></td></tr><tr><td><p>Choroidal effusion</p></td><td style="vertical-align:top"><p>Not known</p></td><td><p>-</p></td></tr><tr><td><p>Vision blurred</p></td><td style="vertical-align:top"><p>Not known</p></td><td><p>-</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial infarction</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Torsade de pointes (potentially fatal)</p></td><td style="vertical-align:top"><p>Not known (see sections 4.4 and 4.5)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vasculitis</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="11" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Change of bowel habit</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Gastritis</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Gingival hyperplasia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Jaundice</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hepatic function abnormal</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="16" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash maculo-papular</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Purpura</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Skin discolouration</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Exanthema</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>Very rare</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>Very rare</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Stevens-Johnson syndrome</p></td><td style="vertical-align:top"><p>Very rare</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Erythema multiforme</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Exfoliative dermatitis</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Quincke&rsquo;s oedema</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Photosensitivity</p></td><td style="vertical-align:top"><p>Cases of photosensitivity reactions have been reported (see section 4.4).</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Ankle swelling</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Possible worsening of pre-existing systemic lupus erythematosus</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Micturition disorder</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Nocturia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pollakiuria</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Renal failure</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Investigations</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight increased</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Electrocardiogram QT prolonged</p></td><td style="vertical-align:top"><p>Not known (see sections 4.4 and 4.5)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Blood glucose increased</p></td><td style="vertical-align:top"><p>Not known</p><p>Appropriateness of these diuretics must be very carefully weighed in patients with gout or diabetes</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Blood uric acid increased</p></td><td style="vertical-align:top"><p>Not known</p><p>Appropriateness of these diuretics must be very carefully weighed in patients with gout or diabetes</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Hepatic enzyme increased</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Very rare**</p></td></tr></tbody></table><p>* responsible for dehydration and orthostatic hypotension. Concomitant loss of chloride ions may lead to secondary compensatory metabolic alkalosis: the incidence and degree of this effect are slight.</p><p>** mostly consistent with cholestasis<br />&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system:</p><p><strong>To report any side effect(s): </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>&nbsp;</p><p>- National Pharmacovigilance Center (NPC)</p><p>- Fax: +966-11-205-7662</p><p>- SFDA call Center 19999</p><p>- Toll free phone: 8002490000</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states: </strong></p><p>&nbsp;</p><p>- Please contact the relevant competent authority.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no information on overdose with Natrixam in humans.</p><p><strong>&nbsp;</strong></p><p><strong><u>For indapamide:</u></strong></p><p><em><u>Symptoms</u></em></p><p>Indapamide has been found free of toxicity at up to 40 mg, <em>i.e</em>. 27 times the therapeutic dose.</p><p>Signs of acute poisoning take the form above all of water/electrolyte disturbances (hyponatraemia, hypokalaemia). Clinically, possibility of nausea, vomiting, hypotension, cramps, vertigo, drowsiness, confusion, polyuria or oliguria possibly to the point of anuria (by hypovolaemia).</p><p><strong><u>&nbsp;</u></strong></p><p><em><u>Treatment</u></em></p><p>Initial measures involve the rapid elimination of the ingested substance(s) by gastric wash-out and/or administration of activated charcoal, followed by restoration of water/electrolyte balance to normal in a specialised centre.</p><p><strong>&nbsp;</strong></p><p><strong><u>For amlodipine:</u></strong></p><p>In humans experience with intentional overdose is limited.</p><p>&nbsp;</p><p><em><u>Symptoms </u></em></p><p>Available data suggest that gross overdose could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.</p><p>&nbsp;</p><p><em><u>Treatment </u></em></p><p>Clinically significant hypotension due to amlodipine overdose calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities and attention to circulating fluid volume and urine output.</p><p>A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2&nbsp;hours after administration of amlodipine 10 mg has been shown to reduce the absorption rate of amlodipine.</p><p>Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: calcic inhibitors and diuretics, ATC code: C08GA02 </strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Mechanism of action</u></strong></p><p>Indapamide is a sulfonamide derivative with an indole ring, pharmacologically related to thiazide diuretics, which acts by inhibiting the reabsorption of sodium in the cortical dilution segment. It increases the urinary excretion of sodium and chlorides and, to a lesser extent, the excretion of potassium and magnesium, thereby increasing urine output and having an antihypertensive action.</p><p><strong>&nbsp;</strong></p><p>Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.</p><p>The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle.</p><p><em>&nbsp;</em></p><p><strong><u>Pharmacodynamic effects</u></strong></p><p>Phase II and III studies using indapamide monotherapy have demonstrated an antihypertensive effect lasting 24 hours. This was present at doses where the diuretic effect was of mild intensity.</p><p>The antihypertensive activity of indapamide is related to an improvement in arterial compliance and a reduction in arteriolar and total peripheral resistance.</p><p>Indapamide reduces left ventricular hypertrophy.</p><p>Thiazide and related diuretics have a plateau therapeutic effect beyond a certain dose, while adverse effects continue to increase. The dose should not be increased if treatment is ineffective.</p><p>It has also been shown, in the short-, mid- and long-term in hypertensive patients, that indapamide:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; does not interfere with lipid metabolism: triglycerides, LDL-cholesterol and HDL-cholesterol;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; does not interfere with carbohydrate metabolism, even in diabetic hypertensive patients.</p><p>&nbsp;</p><p>In patients with hypertension, once daily dosing of amlodipine provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.</p><p>Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.</p><p><em>&nbsp;</em></p><p><strong><u>Clinical efficacy and safety</u></strong></p><p>Natrixam has not been studied on morbidity and mortality.</p><p><em>&nbsp;</em></p><p>In the case of amlodipine, a randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/d in mild to moderate hypertension.</p><p>&nbsp;</p><p>A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke (&gt; 6 months prior to enrollment) or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%). The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction.</p><p><strong>&nbsp;</strong></p><p>There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 95% CI (0.90-1.07) p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs. 7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy. RR 0.96 95% CI [0.89-1.02] p=0.20.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Paediatric population</u></strong></p><p>No data are available with Natrixam in children.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Natrixam in all subsets of the paediatric population (according to the decision of the paediatric investigation plan, in the authorised indication) (see section 4.2 for information on paediatric use).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The co-administration of indapamide and amlodipine does not change their pharmacokinetic properties by comparison to separate administration.</p><p><u>&nbsp;</u></p><p><strong><u>Indapamide</u></strong></p><p>Indapamide 1.5 mg is supplied in a prolonged release dosage based on a matrix system in which the active substance is dispersed within a support which allows sustained release of indapamide.</p><p><strong>&nbsp;</strong></p><p><em><u>Absorption</u></em></p><p>The fraction of indapamide released is rapidly and totally absorbed via the gastrointestinal digestive tract.</p><p>Eating slightly increases the rapidity of absorption but has no influence on the amount of the active substance absorbed.</p><p>Peak serum level following a single dose occurs about 12 hours after ingestion, repeated administration reduces the variation in serum levels between 2 doses.</p><p>Intra-individual variability exists.</p><p><strong>&nbsp;</strong></p><p><em><u>Distribution</u></em></p><p>Binding of indapamide to plasma proteins is 79%.</p><p>The plasma elimination half-life is 14 to 24 hours (mean 18 hours).</p><p>Steady state is achieved after 7 days.</p><p>Repeated administration does not lead to accumulation.</p><p><strong>&nbsp;</strong></p><p><em><u>Elimination</u></em></p><p>Elimination is essentially urinary (70% of the dose) and faecal (22%) in the form of inactive metabolites.</p><p><strong>&nbsp;</strong></p><p><em><u>High risk individuals</u></em></p><p>Pharmacokinetic parameters are unchanged in renal failure patients.</p><p><strong>&nbsp;</strong></p><p><strong><u>Amlodipine</u></strong></p><p>Amlodipine is supplied in an immediate release dosage.</p><p><strong>&nbsp;</strong></p><p><em><u>Absorption, distribution, plasma protein binding</u></em></p><p>After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64 and 80%. The volume of distribution is approximately 21 l/kg. <em>In vitro</em> studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.</p><p>The bioavailability of amlodipine is not affected by food intake.</p><p><strong><em>&nbsp;</em></strong></p><p><em><u>Biotransformation/elimination </u></em></p><p>The terminal plasma elimination half-life is about 35-50 hours and is consistent with once daily dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.</p><p><strong><em>&nbsp;</em></strong></p><p><em><u>Use in hepatic impairment </u></em></p><p>Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic insufficiency have decreased clearance of amlodipine resulting in a longer half-life and an increase in AUC of approximately 40-60%.</p><p><strong><em>&nbsp;</em></strong></p><p><em><u>Use in older people </u></em></p><p>The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly patients. Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Natrixam has not been studied in non-clinical studies.</p><p><strong>&nbsp;</strong></p><p><strong><u>Indapamide</u></strong></p><p>The highest doses administered orally to different animal species (40 to 8,000 times the therapeutic dose) have shown an exacerbation of the diuretic properties of indapamide. The major symptoms of poisoning during acute toxicity studies with indapamide administered intravenously or intraperitoneally were related to the pharmacological action of indapamide, <em>i.e</em>. bradypnoea and peripheral vasodilation.</p><p>Indapamide has been tested negative concerning mutagenic and carcinogenic properties.</p><p>Reproductive toxicity studies have not shown any embryotoxic or teratogenic effect in rat, mice and rabbit.</p><p>Fertility was not impaired either in male or female rats.</p><p><strong>&nbsp;</strong></p><p><strong><u>Amlodipine</u></strong></p><p><em><u>Reproductive toxicology:</u></em></p><p>Reproductive toxicology studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.</p><p><strong><u>&nbsp;</u></strong></p><p><em><u>Impairment of fertility </u></em></p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14&nbsp;days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p>&nbsp;</p><p><em><u>Carcinogenesis, mutagenesis </u></em></p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10&nbsp;mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p>*Based on patient weight of 50 kg</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Tablet core:</u></strong> hypromellose (E464), lactose monohydrate, magnesium stearate (E572), povidone (E1201), silica colloidal anhydrous, calcium hydrogen phosphate dehydrate, cellulose, microcrystalline (E460), croscarmellose sodium (E468), pregelatinized maize starch.</p><p><strong>&nbsp;</strong></p><p><strong><u>Tablet film-coating:</u></strong> glycerol (E422), hypromellose (E464), macrogol 6000, magnesium stearate (E572), titanium dioxide (E171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/Aluminium blisters: 1x15 (15) tablets, 2x15 (30) tablets, 4x15 (60) tablets, 6x15 (90) tablets.</p><p>High density polyethylene tablet container equipped with a screw tamper evident polypropylene cap:&nbsp;</p><p>1x100 (100) tablets, 5x100 (500) tablets.</p><p>Not all pack sizes may be marketed.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder:

Les Laboratoires Servier 

50, rue Carnot

92284 Suresnes cedex 

France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The date of preparation of the package for KSA 10.2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>